SCHEMBL4159842

SCHEMBL4159842

NC(=O)c1ccc2[nH]c3c(c2c1)CCCC3n1cccc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.66
MAPKAPK2 P49137 1/20 0.53
HTR1B P28222 3/20 0.52
SIRT1 Q96EB6 12/20 0.49
HTR1A P08908 2/20 0.48
HTR1D P28221 1/20 0.48
SIRT2 Q8IXJ6 5/20 0.48
SIRT3 Q9NTG7 2/20 0.48
RECQL P46063 1/20 0.48
MAPT P10636 2/20 0.46
ALOX15 P16050 2/20 0.46
MAPK1 P28482 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 1/20 0.45
HTT P42858 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
DRD2 P14416 1/20 0.43
DRD4 P21917 1/20 0.43
HTR1E P28566 1/20 0.43
HTR7 P34969 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4156303 0.90 DHODH (0.67) DHODHMAPKAPK2SIRT1SIRT2SIRT3
SCHEMBL13925700 0.86 DHODH (0.62) DHODHMAPKAPK2SIRT1SIRT2RECQL
SCHEMBL16433425 0.80 DHODH (0.73) DHODHSIRT1SIRT2RECQLGAA
SCHEMBL4152072 0.80 DHODH (1.00) DHODHSIRT1SIRT2SIRT3MAPT
SCHEMBL4160505 0.80 DHODH (0.73) DHODHSIRT1SIRT2SIRT3MAPT
SCHEMBL4157570 0.78 DHODH (0.70) DHODHSIRT1SIRT2HTR7MEN1
SCHEMBL4161207 0.77 DHODH (0.69) DHODHSIRT1MAPTNPSR1MEN1
SCHEMBL4164050 0.77 DHODH (0.69) DHODHMAPKAPK2HTR1BSIRT1HTR1D
SCHEMBL4161484 0.77 DHODH (0.69) DHODHSIRT1SIRT2SIRT3RECQL
SCHEMBL16724477 0.76 DHODH (0.65) DHODHSIRT1SIRT2SIRT3RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-9271960-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2016-03-01 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL PTC THERAPEUTICS, INC. (US) 2015-05-21 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-8946444-B2 Tetrahydrocarbazoles as active agents for inhibiting VEGF production by translational control PTC THERAPEUTICS, INC. (US) 2015-02-03 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control PTC THERAPEUTICS, INC. 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042866-A1 Tetrahydrocarbazoles as Active Agents for Inhibiting VEGF Production by Translational Control VEGFA, FLT4, KDR DHODH 668/4885MAPKAPK2 951/4885HTR1B 4308/4885
US-20150141418-A1 TETRAHYDROCARBAZOLES AS ACTIVE AGENTS FOR INHIBITING VEGF PRODUCTION BY TRANSLATIONAL CONTROL VEGFA, FLT4, KDR DHODH 668/4885MAPKAPK2 951/4885HTR1B 4308/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.